Shanghai Huaota Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd., explained in plain language.
-
New antibody shot could tackle stubborn acne
Disease control Not yet recruitingThis early-stage trial tests a new drug called HB0043, a bispecific antibody that targets two inflammatory proteins (IL-17A and IL-36R) linked to acne. About 21 adults with moderate to severe facial acne will receive either the drug or a placebo. The main goal is to check safety …
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New lung cancer drug HB0025 faces off against standard therapy in major trial
Disease control Not yet recruitingThis Phase 3 trial will test whether a new drug called HB0025, combined with standard chemotherapy, works better than the current treatment tislelizumab plus chemotherapy for people with advanced nonsquamous non-small cell lung cancer. About 500 participants will be randomly assi…
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo aims to outperform standard immunotherapy in lung cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether a new experimental drug called HB0025, combined with chemotherapy, works better than the standard immunotherapy pembrolizumab plus chemotherapy for people with advanced squamous non-small cell lung cancer. About 480 participants who have not had p…
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC